Metabolic and Hemodynamic Effects of Metformin and Glibenclamide in Normotensive NIDDM Patients

Abstract

In normotensive NIDDM patients, treatment with metformin was associated with greater reductions in body weight, plasma total cholesterol concentration, and erect diastolic blood pressure, whereas the systemic vascular resistance index increased after treatment with glibenclamide. These findings merit long-term investigation.